Part 12, Reference for Chapter 143: Melanoma
Skip chapter table of contents and go to main content
- 1 Cutaneous melanoma. Lancet 2014;383(9919):816–27. Cross Ref link Pubmed link , , .
- 2 Increasing incidence of cutaneous melanoma in Queensland, Australia. J Natl Cancer Inst 1992;84:1427–32. Cross Ref link Pubmed link , , , .
- 3 Cutaneous malignant melanoma in Europe. Eur J Cancer 2004;40(16):2355–66. Cross Ref link Pubmed link , .
- 4 Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374–403. Cross Ref link Pubmed link , , , et al.
- 5 Changing epidemiology of malignant cutaneous melanoma in Europe 1953–1997: rising trends in incidence and mortality but recent stabilizations in western. Europe and decreases in Scandinavia. Int J Cancer 2003;107(1):119–26. Cross Ref link Pubmed link , , , .
- 6 GLOBOCAN 2002. Cancer Incidence, Mortality and Prevalence Worldwide. Ed. IARC. CancerBase No. 5 version 2.0. Lyon: IARC Press, 2004. , , , .
- 7 Emerging trends in the epidemiology of melanoma. Br J Dermatol 2014;170(1):11–19. Cross Ref link Pubmed link , .
- 8 National Cancer Institute. SEER Cancer Statistics Factsheets: Melanoma of the Skin. Bethesda, MD: National Cancer Institute http://seer.cancer.gov/statfacts/html/melan.html (last accessed June 2015).
- 9 Melanoma incidence and mortality in Europe: new estimates, persistent disparities. Br J Dermatol 2012;167:1124–30. Cross Ref link Pubmed link , , , et al.
- 10 Melanoma incidence and mortality among US whites, 1969–1999. JAMA 2002;288:1719–20. Cross Ref link Pubmed link , , , et al.
- 11 The changing incidence and mortality of melanoma in Australia. Recent Results. Cancer Res 2002;160:113–21. .
- 12 Melanoma epidemiology and trends. Clin Dermatol 2009;27(1):3–9. Cross Ref link Pubmed link , .
- 13 Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol 2008;128:2905–8. Cross Ref link Pubmed link , , , .
- 14 Rising melanoma incidence rates of the trunk among younger women in the United States. Cancer Epidemiol Biomarkers Prev 2010;19:2401–6. Cross Ref link Pubmed link , , , et al.
- 15 A unique gender difference in early onset melanoma implies that in addition to ultraviolet light exposure other causative factors are important. Pigment Cell Melanoma Res 2013;26:128–35. Cross Ref link Pubmed link , , , et al.
- 16 Time trends of incidence of age‐associated diseases in the US elderly population: Medicare‐based analysis. Age Ageing 2013;42:494–500. Cross Ref link Pubmed link , , , et al.
- 17 The relationship between melanoma thickness and time to diagnosis in a large population‐based study. Arch Dermatol 2006;142:1422–7. Cross Ref link Pubmed link , , , et al.
- 18 Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000;89:1269–78. Cross Ref link Pubmed link , , .
- 19 Increasing burden of melanoma in the United States. J Invest Dermatol 2009;129:1666–74. Cross Ref link Pubmed link , , , et al.
- 20 Trends in the survival of patients diagnosed with malignant melanoma of the skin in the Nordic countries 1964–2003 followed up to the end of 2006. Acta Oncol 2010;49:665–72. Cross Ref link Pubmed link , , , et al.
- 21 Trends of cutaneous melanoma in the Netherlands: increasing incidence rates among all Breslow thickness categories and rising mortality rates since 1989. Ann Oncol 2012;23:524–30. Cross Ref link Pubmed link , , , et al.
- 22 Thick melanoma: the challenge persists. Br J Dermatol 2005;152:104–9. Cross Ref link Pubmed link , , .
- 23 Cancer statistics, 2013. CA Cancer J Clin 2013 ;63(1):11–30. Cross Ref link Pubmed link , , .
- 24 Australian Institute of Health and Welfare. Australian Cancer Incidence and Mortality (ACIM) books http://www.aihw.gov.au/acim‐books/ (last accessed August 2015).
- 25 On the clinical significance of cutaneous melanoma's precursors. Indian Dermatol Online J 2012;3(2):83–8. Cross Ref link Pubmed link
- 26 Melanoma risk in congenital melanocytic naevi: a systematic review. Br J Dermatol 2006;155(1):1–8. Cross Ref link Pubmed link , , .
- 27 The risk of melanoma in patients with congenital nevi: a cohort study. J Am Acad Dermatol 1995;32(4):595–9. Cross Ref link Pubmed link , , .
- 28 Congenital melanocytic nevi: clinical and histopathologic features, risk of melanoma, and clinical management. J Am Acad Dermatol 2005;52(2):197–203. Cross Ref link Pubmed link , , , .
- 29 Malignant melanoma in children. A review. Arch Dermatol 1997;133(3):363–71. Cross Ref link Pubmed link , .
- 30 Risk of melanoma arising in large congenital melanocytic nevi: a systematic review. Plast Reconstr Surg 2004;113(7):1968–74. Cross Ref link Pubmed link , , .
- 31 Large congenital melanocytic nevi: therapeutic management and melanoma risk: a systematic review. J Am Acad Dermatol 2013;68(3):493‐8.e1‐14. Cross Ref link Pubmed link , , .
- 32 Congenital melanocytic nevi frequently harbor NRAS mutations but no BRAF mutations. J Invest Dermatol 2007;127(1):179–82. Cross Ref link Pubmed link , , , .
- 33 Nonepidermal origin of malignant melanoma associated with a giant congenital nevocellular nevus. Plast Reconstr Surg 1981;67(6):782–90. Cross Ref link Pubmed link , , , .
- 34 Small congenital nevocellular nevi and the risk of cutaneous melanoma. J Pediatr 1982;100(2):219–24. Cross Ref link Pubmed link , .
- 35 The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population‐based estimate. Arch Dermatol 2003;139(3):282–8. Cross Ref link Pubmed link , , , .
- 36 National Institute of Health (NIH). Diagnosis and treatment of early melanoma. NIH Consensus Development Conference. Consensus Statement 1992 Jan 27–29;10(1):1–25.
- 37 Prevalence of dysplastic naevi in a community practice. Lancet 1984;1:729. Cross Ref link Pubmed link , .
- 38 A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol 1984;15:1147–65. Cross Ref link Pubmed link , , , et al.
- 39 Tumor progression in the human melanocytic system. Anticancer Res 1989;9(4):865–72. Pubmed link , , , et al.
- 40 Risks of cutaneous melanoma in relation to the numbers, types, and sites of naevi: A case–control study. Br J Cancer 1996;73:1605–11. Cross Ref link Pubmed link , , , et al.
- 41 Clinically recognized dysplastic nevi: A central risk factor for cutaneous melanoma. JAMA 1997;277:1439–44. Cross Ref link Pubmed link , , , et al.
- 42 Atypical (dysplastic) nevi: outcomes of surgical excision and association with melanoma. JAMA Dermatol 2013;149(8):928–34. Cross Ref link Pubmed link , , , et al.
- 43 Familial melanoma: a meta‐analysis and estimates of attributable fraction. Cancer Epidemiol Biomarkers Prev 2010;19(1):65–73. Cross Ref link Pubmed link , , .
- 44 The validity and practicality of sun‐reactive skin types I through VI. Arch Dermatol 1988;124(6):869–71. Cross Ref link Pubmed link
- 45 Meta‐analysis of risk factors for cutaneous melanoma: III. Family history, actinic damage and phenotypic factors. Eur J Cancer 2005;41(14):2040–59. Cross Ref link Pubmed link , , , et al.
- 46 Count of benign melanocytic nevi as a major indicator of risk for nonfamilial nodular and superficial spreading melanoma. Cancer 1990;66(2):387–95. Cross Ref link Pubmed link , , , et al.
- 47 Role of sun exposure on nevus. First study in age‐sex phenotype‐controlled populations. Arch Dermatol 1993;129(10):1280–5. Cross Ref link Pubmed link , , , et al.
- 48 Origin of familial malignant melanomas from heritable melanocytic lesions. 'The B‐K mole syndrome'. Arch Dermatol 1978;114(5):732–8. Cross Ref link Pubmed link Jr, , , et al.
- 49 Precursor naevi in cutaneous malignant melanoma: a proposed nomenclature. Lancet 1980;2:1024. Cross Ref link Pubmed link , , , et al.
- 50 High risk of malignant melanoma in melanoma‐prone families with dysplastic nevi. Ann Intern Med 1985;102:458–65. Cross Ref link Pubmed link , Jr, , et al.
- 51 How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 1993;29(6):989–96. Cross Ref link Pubmed link , , , et al.
- 52 Meta‐analysis of risk factors for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer 2005;41(1):28–44. Cross Ref link Pubmed link , , , et al.
- 53 Risk of melanoma and other cancers in melanoma‐prone families. J Invest Dermatol 1993;100(3):350S–5S. Cross Ref link Pubmed link , , , et al.
- 54 ARF promotes MDM2 degradation and stabilizes p53: ARF‐INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways. Cell 1998;92(6):725–34. Cross Ref link Pubmed link , , .
- 55 Genome‐wide associations studies for melanoma and nevi. Pigment Cell Melanoma Res 2009;22(5):527–8. Cross Ref link Pubmed link , .
- 56 Increased risk of pancreatic cancer in melanoma‐prone kindreds with p16INK4 mutations. N Engl J Med 1995;12;333(15):970–4. Cross Ref link Pubmed link , , , et al.
- 57 Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma‐prone families from three continents. J Med Genet 2007;44(2):99–106. Cross Ref link Pubmed link , , , et al.
- 58 Characterization of ligurian melanoma families and risk of occurrence of other neoplasia. Int J Cancer 1999;83(4):441–8 Cross Ref link Pubmed link , , , et al.
- 59 CDKN2A mutations in multiple primary melanomas. N Engl J Med 1998;26;338(13):879–87. Cross Ref link Pubmed link , , , et al.
- 60 French Hereditary Melanoma Study Group. Sporadic multiple primary melanoma cases: CDKN2A germline mutations with a founder effect. Genes Chromosomes Cancer 2001;32(3):195–202. Cross Ref link Pubmed link , , , et al.
- 61 Geographical variation in the penetrance of CDKN2A mutations for melanoma. J Natl Cancer Inst 2002 19;94(12):894–903. Cross Ref link Pubmed link , , , et al.
- 62 Influence of genes, nevi, and sun sensitivity on melanoma risk in a family sample unselected by family history and in melanoma‐prone families. J Natl Cancer Inst 2004;19;96(10):785–95. Cross Ref link Pubmed link , , , et al.
- 63 Germline melanoma susceptibility and prognostic genes: a review of the literature. J Am Acad Dermatol 2012;67(5):1055–67. Cross Ref link Pubmed link , , .
- 64 Prevalence of p16 and CDK4 germline mutations in 48 melanoma‐prone families in France. The French Familial Melanoma Study Group. Hum Mol Genet 1998;7(2):209–16. , , , et al.
- 65 Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma. Nat Genet 1996;12(1):97–9. Cross Ref link Pubmed link , , , et al.
- 66 Identification of a CDK4 R24H mutation‐positive melanoma family by analysis of early‐onset melanoma patients in Latvia. Melanoma Res 2009;19(2):119–22. Cross Ref link Pubmed link , , , et al.
- 67 Comprehensive field synopsis and systematic meta‐analyses of genetic association studies in cutaneous melanoma. J Natl Cancer Inst 2011;17;103(16):1227–35. Cross Ref link Pubmed link , , , et al.
- 68 Variants of the melanocyte‐stimulating hormone receptor gene are associated with red hair and fair skin in humans. Nat Genet 1995;11(3):328–30. Cross Ref link Pubmed link , , , et al.
- 69 The Asp84Glu variant of the melanocortin 1 receptor (MC1R) is associated with melanoma. Hum Mol Genet 1996;5:1663–6. Cross Ref link Pubmed link , , , et al.
- 70 Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J Invest Dermatol 2001;117(2):294–300. Cross Ref link Pubmed link , , , et al.
- 71 MC1R genotype modifies risk of melanoma in families segregating CDKN2A mutations. Am J Hum Genet 2001;69(4):765–73. Cross Ref link Pubmed link , , , et al.
- 72 Association of MC1R variants and risk of melanoma in melanoma‐prone families with CDKN2A mutations. Cancer Epidemiol Biomarkers Prev 2005;14(9):2208–12. Pubmed link , , , et al.
- 73 Genetic variants in pigmentation genes, pigmentary phenotypes, and risk of skin cancer in Caucasians. Int J Cancer 2009;125(4):909–17. Cross Ref link Pubmed link , , , .
- 74 Variants at chromosome 20 (ASIP locus) and melanoma risk. Int J Cancer 2013;Jan 1;132(1):42–54. Cross Ref link Pubmed link , , , et al.
- 75 Common sequence variants on 20q11.22 confer melanoma susceptibility. Nat Genet 2008;40(7):838–40. Cross Ref link Pubmed link , , , et al.
- 76 Two newly identified genetic determinants of pigmentation in Europeans. Nat Genet 2008;40(7):835–7. Cross Ref link Pubmed link , , , et al.
- 77 SLC45A2: a novel malignant melanoma‐associated gene. Hum Mutat 2008;29:1161–7. Cross Ref link Pubmed link , , , et al.
- 78 Genome‐wide association study identifies three loci associated with melanoma risk. Nat Genet 2009;41:920–8. Cross Ref link Pubmed link , , , et al.
- 79 Pigmentation‐related genes and their implication in malignant melanoma susceptibility. Exp Dermatol 2009;18:634–42. Cross Ref link Pubmed link , , , et al.
- 80 Multiple pigmentation gene polymorphisms account for a substantial proportion of risk of cutaneous malignant melanoma. J Invest Dermatol 2010;130(2):520–8. Cross Ref link Pubmed link , , , et al.
- 81 Fifteen‐year quest for microphthalmia‐associated transcription factor target genes. Pigment Cell Melanoma Res 2010;23(1):27–40. Cross Ref link Pubmed link , , , .
- 82 MiTF regulates cellular response to reactive oxygen species through transcriptional regulation of APE‐1/Ref‐1. J Invest Dermatol 2009;129(2):422–31. Cross Ref link Pubmed link , , .
- 83 A novel recurrent mutation in MITF predisposes to familial and sporadic melanoma. Nature 2011;480(7375):99–103. Cross Ref link Pubmed link , , , et al.
- 84 A SUMOylation‐defective MITF germline mutation predisposes to melanoma and renal carcinoma. Nature 2011;480:94–8. Cross Ref link Pubmed link , , , et al.
- 85 Prevalence of the E318K MITF germline mutation in Italian melanoma patients: associations with histological subtypes and family cancer history. Pigment Cell Melanoma Res 2013;26(2):259–62. Cross Ref link Pubmed link , , , et al.
- 86 BAP1 cancer syndrome: malignant mesothelioma, uveal and cutaneous melanoma, and MBAITs. J Transl Med 2012;10:179. Cross Ref link Pubmed link , , , et al.
- 87 Germline BAP1 inactivation is preferentially associated with metastatic ocular melanoma and cutaneous‐ocular melanoma families. PLOS One 2012;7(4):e35295. Cross Ref link Pubmed link , , , et al.
- 88 DNA repair gene polymorphisms and risk of cutaneous melanoma: a systematic review and meta‐analysis. Carcinogenesis 2009;30(10):1735–43. Cross Ref link Pubmed link , , .
- 89 Single‐nucleotide polymorphisms in DNA‐repair genes and cutaneous melanoma. Mutat Res 2010;30;702(1):8–16. Cross Ref link Pubmed link , , , et al.
- 90 Single nucleotide polymorphisms in DNA repair genes XRCC1 and APEX1 in progression and survival of primary cutaneous melanoma patients. Mutat Res 2009;10;661(1–2):78–84. Cross Ref link Pubmed link , , , et al.
- 91 Impact of gene polymorphisms on clinical outcome for stage IV melanoma patients treated with biochemotherapy: an exploratory study. Clin Cancer Res 2005;1;11(3):1237–46. Pubmed link , , , et al.
- 92 Vitamin D and skin cancer: a meta‐analysis. Eur J Cancer 2009;45(4):634–41. Cross Ref link Pubmed link , , , et al.
- 93 Association between cutaneous melanoma, Breslow thickness and vitamin D receptor BsmI polymorphism. Br J Dermatol 2007;156(2):277–82. Cross Ref link Pubmed link , , , et al.
- 94 Meta‐analysis of risk factors for cutaneous melanoma: II. Sun exposure. Eur J Cancer 2005;41(1):45–60. Cross Ref link Pubmed link , , , et al.
- 95 Sun exposure and risk of melanoma. Arch Dis Child 2006;91(2):131–8. Cross Ref link Pubmed link , , , et al.
- 96 Early‐life sun exposure and risk of melanoma before age 40 years. Cancer Causes Control 2011;22(6):885–97. Cross Ref link Pubmed link , , , et al.
- 97 Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol 2006;24(19):3172–7. Cross Ref link Pubmed link , , , et al.
- 98 Relationship of cutaneous malignant melanoma to individual sunlight‐exposure habits. J Natl Cancer Inst 1986;76(3):403–14. Pubmed link , , .
- 99 Risk factors for childhood melanoma in Queensland, Australia. Int J Cancer 1997;70(1):26–31. Cross Ref link Pubmed link , , , .
- 100 Divergent cancer pathways for early‐onset and late‐onset cutaneous malignant melanoma. Cancer 2009;115(18):4176–85. Cross Ref link Pubmed link , , , .
- 101 Association of cutaneous malignant melanoma with intermittent exposure to ultraviolet radiation: results of a case–control study in Ontario, Canada. Int J Epidemiol 1999;28(3):418–27. Cross Ref link Pubmed link , , .
- 102 A comprehensive catalogue of somatic mutations from a human cancer genome. Nature 2010;463(7278):191–6. Cross Ref link Pubmed link , , , et al.
- 103 A landscape of driver mutations in melanoma. Cell 2012;150:251–63. Cross Ref link Pubmed link , , , et al.
- 104 Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 2012;9;485(7399):502–6. , , , et al.
- 105 DNA repair and cell cycle checkpoint defects as drivers and therapeutic targets in melanoma. Pigment Cell Melanoma Res 2013;26(6):805–16. Cross Ref link Pubmed link , , , .
- 106 The pathogenesis of melanoma induced by ultraviolet radiation. N Engl J Med 1999;340(17):1341–8. Cross Ref link Pubmed link , , , .
- 107 Induction of nevi and skin tumors in Ink4a/Arf Xpa knockout mice by neonatal, intermittent, or chronic UVB exposures. Cancer Res 2006;Mar 1;66(5):2608–15. Cross Ref link Pubmed link , , , et al.
- 108 Cutaneous melanoma. In: Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, Wolff K, eds. Fitzpatrick's Dermatology in General Medicine. New York: McGraw‐Hill, 2012:1416–44. , , , et al.
- 109 Childhood sun exposure as a risk factor for melanoma: a systematic review of epidemiologic studies. Cancer Causes Control 2001;12:69–82. Cross Ref link Pubmed link , , .
- 110 Risk factors in elderly people for lentigo maligna compared with other melanomas: a double case–control study. Arch Dermatol 2009;145(4):418–23. Pubmed link , , , et al.
- 111 Cutaneous malignant melanoma and indicators of total accumulated exposure to the sun: an analysis reporting histogenetic types. J Natl Cancer Inst 1984;73:75–82. Pubmed link , .
- 112 Role of sun exposure in the etiology of malignant melanoma: epidemiologic inference. J Natl Cancer Inst 1973;51(3):777–9. Pubmed link , .
- 113 Melanoma risk and residence in sunny areas. EORTC Melanoma Co‐operative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1997;76:1521–4. Cross Ref link Pubmed link , , , et al.
- 114 Country of origin, age at migration and risk of cutaneous melanoma: a migrant cohort study of 1,100,000 Israeli men. Int J Cancer 2013;15;133(2):486–94. Cross Ref link Pubmed link , , , et al.
- 115 Nonfamilial cutaneous melanoma incidence in women associated with sun exposure before 20 years of age. Pediatrics 1989;84(2):119–204. Pubmed link , , , et al.
- 116 The Danish case–control study of cutaneous malignant melanoma. II. Importance of UV‐light exposure. Int J Cancer 1988;45(3):319–24. Cross Ref link , , .
- 117 Sunburns and risk of cutaneous melanoma: does age matter? A comprehensive meta‐analysis. Ann Epidemiol 2008;18(8):614–27. Cross Ref link Pubmed link , , , et al.
- 118 Tanning beds, sunlamps, and risk of cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005;14(3):562–6. Cross Ref link Pubmed link , , .
- 119 A multicentre epidemiological study on sunbed use and cutaneous melanoma in Europe. Eur J Cancer 2005;41(14):2141–9. Cross Ref link Pubmed link , , , et al.
- 120 Public awareness about risk factors could pose problems for case–control studies: the example of sunbed use and cutaneous melanoma. Eur J Cancer 2005;41(14):2150–4. Cross Ref link Pubmed link , , , et al.
- 121 Risk factors for skin cancers: a nested case–control study within the nurses' health study. Int J Epidemiol 2006;35(6),1514–21. Cross Ref link Pubmed link , , .
- 122 Tanning bed exposure increases the risk of malignant melanoma. Int J Epidemiol 2007;46(12):1253–7. , , , et al.
- 123 Reviews on sun exposure and artificial light and melanoma. Prog Biophys Mol Biol 2011;Dec;107(3):362–6. Cross Ref link Pubmed link , , .
- 124 Cutaneous melanoma attributable to sunbed use: systematic review and meta‐analysis. BMJ 2012;345:e4757. Cross Ref link Pubmed link , , , .
- 125 The PUVA‐induced pigmented macule: a lentiginous proliferation of large, sometimes cytologically atypical, melanocytes. J Am Acad Dermatol 1983;9:47–58. Cross Ref link Pubmed link , , .
- 126 Cutaneous pigmented melanocytic tumor in a mouse treated with psoralen plus ultraviolet A radiation. Photodermatol Photoimmunol Photomed 1990;7:28–31. Pubmed link , , .
- 127 Effect of psoralen plus ultraviolet A radiation on in vivo growth of melanoma cells. Cancer Res 1991;51:589–7. , , .
- 128 PUVA and cancer risk: the Swedish follow‐up study. Br J Dermatol 1999;Jul;141(1):108–12. Cross Ref link Pubmed link , , , et al.
- 129 Malignant melanoma in patients treated for psoriasis with methoxsalen (psoralen) and ultraviolet A radiation (PUVA). The PUVA follow‐up study. N Engl J Med 1997;336:1041–5. Cross Ref link Pubmed link , , .
- 130 PUVA Follow up Study. The risk of melanoma in association with long‐term exposure to PUVA. J Am Acad Dermatol 2001;44(5):755–61. Cross Ref link Pubmed link ;
- 131 ‘High single‐dose’ European PUVA regimen also causes an excess of non‐melanoma skin cancer. Br J Dermatol 1991;124:49–55. Cross Ref link Pubmed link , , , et al.
- 132 Psoriasis, its treatment, and cancer in a cohort of Finnish Patients. J Invest Dermatol 2000;114:587–90. Cross Ref link Pubmed link , , , et al.
- 133 Carcinogenic risks of psoralen UV‐A therapy and narrowband UV‐B therapy in chronic plaque psoriasis: a systematic literature review. J Eur Acad Dermatol Venereol 2012;26 Suppl. 3:22–31. Cross Ref link Pubmed link , , , et al.
- 134 No evidence for increased skin cancer risk in psoriasis patients treated with broadband or narrowband UVB phototherapy: a first retrospective study. Acta Derm Venereol 2004;84:370–4. Cross Ref link Pubmed link , , , et al.
- 135 The photocarcinogenic risk of narrowband UVB (TL‐01) phototherapy: early follow‐up data. Br J Dermatol 2005;152:755–7. Cross Ref link Pubmed link , , , et al.
- 136 Photocarcinogenic risk of narrowband ultraviolet B (TL‐01) phototherapy: early follow‐up data. Br J Dermatol 2006;154:566–7. Cross Ref link Pubmed link , .
- 137 Incidence of skin cancers in 3867 patients treated with narrow‐band ultraviolet B phototherapy. Br J Dermatol 2008;159:931–5. Cross Ref link Pubmed link , , , et al.
- 138 Selection criteria for genetic assessment of patients with familial melanoma. J Am Acad Dermatol 2009;61(4):677.e1–14. Cross Ref link , , , et al.
- 139 Genetic testing for melanoma. Lancet Oncol 2002;3(11):653–4. Cross Ref link Pubmed link , , , et al.
- 140 Cancer Incidence and Mortality Worldwide. IARC CancerBase No. 10 [internet]. International Agency for Research on Cancer, 2010, Lyon, France , , , et al. GLOBOCAN 2008 v1.2,
- 141 Reduced melanoma risk after regular sunscreen use: randomized trial follow‐up. J Clin Oncol 2011;29(3):257–63. Cross Ref link Pubmed link , , , .
- 142 Interventional study in 1,232 young German children to prevent the development of melanocytic nevi failed to change sun exposure and sun protective behavior. Int J Cancer 2005;116(5)755:61. Cross Ref link Pubmed link , , , et al.
- 143 Skin protection by sunscreens is improved by explicit labeling and providing free sunscreen. J Invest Dermatol 2007;127(1):41–8. Cross Ref link Pubmed link , , , et al.
- 144 Chemoprevention of melanoma. Adv Pharmacol 2012;65:361–98. Cross Ref link Pubmed link , .
- 145 Personal risk‐factor chart for cutaneous melanoma. Lancet 1989;2(8661):487–90. Cross Ref link Pubmed link , , .
- 146 How common is the atypical mole syndrome phenotype in apparently sporadic melanoma? J Am Acad Dermatol 1993;29(6):989–96. Cross Ref link Pubmed link , , , et al.
- 147 Risk factors and individual probabilities of melanoma for whites. J Clin Oncol 2005;23(12):2699–75. , , , .
- 148 Risk factors for presumptive melanoma in skin cancer screening: American Academy of Dermatology National Melanoma/Skin Cancer Screening Program experience 2001–2005. J Am Acad Dermatol 2007;57:60–6. Cross Ref link Pubmed link , , , et al.
- 149 Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25(9):1129–34. Cross Ref link Pubmed link , , , et al.
- 150 The classification of malignant melanoma and its histologic reporting. Cancer 1973;32:1446–57. Cross Ref link Pubmed link , , , et al.
- 151 Invasive malignant melanomas lacking competence for metastasis. Am J Dermatopathol 1984;Summer;6 Suppl.:55–61. Pubmed link , , , et al.
- 152 p53 expression and risk factors for cutaneous melanoma: a case–control study. Int J Cancer 1998;77(6):843–8. Cross Ref link Pubmed link , , .
- 153 Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst 2003;95:806–12. Cross Ref link Pubmed link , , , et al.
- 154 The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res 2011;24(5):879–97. Cross Ref link Pubmed link , , .
- 155 The kinetics of the visible growth of a primary melanoma reflects the tumor aggressiveness and is an independent prognostic marker: a prospective study. Int J Cancer 2002;102(1):34–8. Cross Ref link Pubmed link , , , et al.
- 156 Rate of growth in melanomas: characteristics and associations of rapidly growing melanomas. Arch Dermatol 2006;142(12):1551–8. Pubmed link , , , et al.
- 157 Defining fast‐growing melanomas: reappraisal of epidemiological, clinical, andhistological features. Melanoma Res 2011;21(2):131–8. Cross Ref link Pubmed link , , , .
- 158 Growth rate as a prognostic factor in localized invasive cutaneous melanoma. J Eur Acad Dermatol Venereol 2010;24(2):147–54. Cross Ref link Pubmed link , , , .
- 159 Prediction of sentinel lymph node positivity by growth rate of cutaneous melanoma. Arch Dermatol 2012;148(5):577–84. Pubmed link , , , et al.
- 160 Correlation of subjective self‐reported melanoma growth rate with objective tumor proliferation markers. Arch Dermatol 2008;144(4):555–6. Pubmed link , , , et al.
- 161 Prevalence of BRAF and NRAS mutations in fast‐growing melanomas. Pigment Cell Melanoma Res 2013;26(3):429–31. Cross Ref link Pubmed link , , , et al.
- 162 Distinct sets of genetic alterations in melanoma. N Engl J Med 2005;353(20):2135–47. Cross Ref link Pubmed link , , , .
- 163 Mutations of the BRAF gene in human cancer. Nature 2002;417(6892):949–54. Cross Ref link Pubmed link , , , .
- 164 Evolving concepts in melanoma classification and their relevance to multidisciplinary melanoma patient care. Mol Oncol 2011;5(2):124–36. Cross Ref link Pubmed link , , .
- 165 Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: A meta‐analysis. Br J Dermatol 2011;164:776–84. Cross Ref link Pubmed link , , .
- 166 Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006;24:4340–6. Cross Ref link Pubmed link , , , .
- 167 Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457:599–602. Cross Ref link Pubmed link , , , et al.
- 168 Mutations in GNA11 in uveal melanoma. N Engl J Med 2010;363:2191–9. Cross Ref link Pubmed link , , , et al.
- 169 Genetic and morphologic features for melanoma classification. Pigment Cell Melanoma Res 2010;23:763–70. Cross Ref link Pubmed link , , , et al.
- 170 Bastian Improving melanoma classification by integrating genetic and morphologic features. PLOS Med 2008;5:e120. Cross Ref link Pubmed link , , , et al.
- 171 ABCDs of melanoma. Cutis 1995;56(6):313. Pubmed link .
- 172 Clinical recognition of early invasive malignant melanoma. BMJ 1990;301(6759):1005–6. Cross Ref link Pubmed link .
- 173 First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005;141(4):434–8. Cross Ref link Pubmed link , , , et al.
- 174 Superiority of a cognitive education with photographs over ABCD criteria in the education of the general population to the early detection of melanoma: a randomized study. Int J Cancer 2006;118:2276–80. Cross Ref link Pubmed link , , , et al.
- 175 The 'ugly duckling' sign: identification of the common characteristics of nevi in an individual as a basis for melanoma screening. Arch Dermatol 1998;134(1):103–4. Cross Ref link Pubmed link , .
- 176 Evidence of a limited intra‐individual diversity of nevi: intuitive perception of dominant clusters is a crucial step in the analysis of nevi by dermatologists. J Invest Dermatol 2013;133(10):2355–61. Cross Ref link Pubmed link , , , et al.
- 177 Systematic review of the diagnostic accuracy of dermatoscopy in detecting malignant melanoma. Med J Aust 1997;167(4):206–10. Pubmed link .
- 178 Reflectance‐mode confocal microscopy of pigmented skin lesions – improvement in melanoma diagnostic specificity. J Am Acad Dermatol 2005;53(6):979–85. Cross Ref link Pubmed link , , .
- 179 Development of a two‐step method for the diagnosis of melanoma by reflectance confocal microscopy. J Am Acad Dermatol 2009;61(2):216–29. Cross Ref link Pubmed link , , , , .
- 180 Incidence of non cutaneous melanomas in the US. Cancer 2005;103(5):1000–7. Cross Ref link Pubmed link , , , et al.
- 181 Uveal and conjunctival malignant melanoma in denmark 1943–97: observed and relative survival of patients followed through 2002. Ophthalmic Epidemiol 2006;13(2):85–96. Cross Ref link Pubmed link , , , .
- 182 Prognostic value of clinical and histopathological parameters in conjunctival melanomas: a retrospective study. Br J Ophthalmol 2002;86(2):163–7. Cross Ref link Pubmed link , , , et al.
- 183 Malignant melanoma of unknown primary site. To make the long story short. A systematic review of the literature. Crit Rev Oncol Hematol 2011;78(2):112–26. Cross Ref link Pubmed link , , .
- 184 Metastatic melanoma to lymph nodes in patients with unknown primary sites. Cancer 2006;106(9):2012–20. Cross Ref link Pubmed link , , , et al.
- 185 Melanoma of unknown primary site: presentation, treatment, and prognosis — A single institution study. Cancer 1997;79:1816–21. Cross Ref link Pubmed link , , , et al.
- 186 Melanoma and tumor thickness: challenges of early diagnosis. Arch Dermatol 1999;135(3):269–74. Cross Ref link Pubmed link , , , et al.
- 187 Delay in the diagnosis of cutaneous malignant melanoma. A prospective study in 250 patients. Cancer 1991;68(9):2064–8. Cross Ref link Pubmed link , , , et al.
- 188 Melanoma detection in British Columbia, Canada. J Am Acad Dermatol 2005;52(1):48–54. Cross Ref link Pubmed link , , , .
- 189 Factors associated with a high tumour thickness in patients with melanoma. Br J Dermatol 2007;156(5):938–44. Cross Ref link Pubmed link , , , et al.
- 190 Time trends of incidence of age‐associated diseases in the US elderly population: Medicare‐based analysis. Age Ageing 2013;42:494–500. Cross Ref link Pubmed link , , , et al.
- 191 Factors related to the presentation of thin and thick nodular melanoma from a population based cancer registry in Queensland Australia. Cancer 2009;115:1318–27. Cross Ref link Pubmed link , , , et al.
- 192 Crafting a melanoma educational campaign to reach middle‐aged and older men. J Cutan Med Surg 2006;10(6):259–68. Cross Ref link Pubmed link , , , et al.
- 193 Dermatologist detection and skin self‐examination are associated with thinner melanomas: results from a survey of the Italian Multidisciplinary Group on Melanoma. Arch Dermatol 2003;139(5):607–12. Cross Ref link Pubmed link , , , et al.
- 194 Efficacy of skin self‐examination practices for early melanoma detection. Cancer Epidemiol Biomarkers Prev 2009;18(11):3018–23. Cross Ref link Pubmed link , , , et al.
- 195 Systematic skin cancer screening in Northern Germany. J Am Acad Dermatol 2012;66(2):201–11. Cross Ref link Pubmed link , , , et al.
- 196 Effect of public education aimed at early diagnosis of malignant melanoma: cohort comparison study. BMJ 2003;326:367. Cross Ref link Pubmed link , , .
- 197 Cost‐effectiveness in skin cancer prevention In: Altmeyer P, Hoffmann K, Stucker M, eds. Skin Cancer and UV Radiation. Berlin: Springer‐Verlag, 1997. .
- 198 Delays in diagnosis and melanoma prognosis (I): the role of patients. Int J Cancer 2000;89:271–9. Cross Ref link Pubmed link , , , et al.
- 199 Delays in diagnosis and melanoma prognosis (II): the role of doctors. Int J Cancer 2000;89:280–5. Cross Ref link Pubmed link , , , et al.
- 200 Early detection of malignant melanoma: the role of physician examination and self‐examination of the skin. CA Cancer J Clin 1985;35:130–51. Cross Ref link Pubmed link , , .
- 201 Cognitive training with photographs as a new concept in an education campaign for self‐detection of melanoma: a pilot study in the community. J Eur Acad Dermatol Venereol 2011;25(9):1099–103. Cross Ref link Pubmed link , , , et al.
- 202 Histopathology and precursor lesions. In: Balch CM, Houghton AN, Sober AJ, Soong SJ, eds. Cutaneous Melanoma. St Louis, Missouri: Quality Medical Publishing, 1998:65–79. , .
- 203 Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mol Pathol 2006;19 Suppl. 2:S34–40. Cross Ref link .
- 204 Pathology of Melanocytic Nevi and Malignant Melanoma. Boston: Butterworth‐Heinemann, 1995.
- 205 The histopathology of cutaneous malignant melanoma. Semin Diagn Pathol 1993;10(1):47–75. Pubmed link , .
- 206 Benign pigmented lesions and malignant melanoma. In: Elder E, Elenitsas R, Jaworsky C, Johnson B , eds. Lever's Histopathology of the Skin, 8th edn. Philadelphia: Lippincott‐Raven, 1997:625–84. , .
- 207 Nevoid malignant melanoma. Arch Dermatol Res 1985;277(5):362–9. Cross Ref link Pubmed link , , .
- 208 Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz 2008. Am J Surg Pathol 2010;34:314–26. Cross Ref link Pubmed link , , , et al.
- 209 A diagnosis for maniacs. Am J Dermatopathol 2000;22(6):556–8. Cross Ref link Pubmed link .
- 210 Desmoplastic malignant melanoma (a rare variant of spindle cell melanoma). Cancer 1971;28(4):914–36. Cross Ref link Pubmed link , , .
- 211 Spitzoid melanoma. Clin Dermatol 2009;27(6):545–55. Cross Ref link Pubmed link .
- 212 Unusual variants of malignant melanoma. Clin Dermatol 2009;27(6):564–87. Cross Ref link Pubmed link , .
- 213 Immunohistochemical demonstration of S100 protein in malignant melanoma and pigmented nevus, and its diagnostic application. Cancer 1982;50(5):912–18. Cross Ref link Pubmed link , , , et al.
- 214 Immunohistochemical analysis of cutaneous malignant melanoma: comparison of S‐100 protein, HMB‐45 monoclonal antibody and NKI/C3 monoclonal antibody. Pathology 1994;26(1):16–19. Cross Ref link Pubmed link , , .
- 215 Molecular cytogenetics of cutaneous melanocytic lesions – diagnostic, prognostic and therapeutic aspects. Histopathology 2010;56(1):121–32. Cross Ref link Pubmed link , , .
- 216 Molecular diagnosis in dermatopathology: what makes sense, and what doesn't. Exp Dermatol 2009;18(1):12–23. Cross Ref link Pubmed link , , .
- 217 Molecular pathology and patient care. Mol Med 2010;107(2):86–93. .
- 218 Fluorescence in situ hybridization (FISH) as an ancillary diagnostic tool in the diagnosis of melanoma. Am J Surg Pathol 2009;33(8):1146–56. Cross Ref link Pubmed link , , , et al.
- 219 Fluorescence in‐situ hybridization analysis for melanoma diagnosis. Histopathology 2012;60(5):706–14. Cross Ref link Pubmed link , , .
- 220 Metastatic pattern of malignant melanoma. A study of 216 autopsy cases. Am J Surg 1978;135(6):807–10. Cross Ref link Pubmed link , , , .
- 221 Data on first recurrence after treatment for malignant melanoma in a large patient population. Plast Reconstr Surg 1993;91(1):94–8. Cross Ref link Pubmed link , .
- 222 Patterned distribution of metastases from malignant melanoma in humans. Cancer Res 1983;43(7):3427–33. Pubmed link , , .
- 223 Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 1992;16(2):191–5. Cross Ref link Pubmed link , , , et al.
- 224 Thickness, cross‐sectional areas and depth of invasion in the prognosis of cutaneous melanoma. Ann Surg 1970;172(5):902–8. Cross Ref link Pubmed link .
- 225 Tumor thickness, level of invasion and node dissection in stage I cutaneous melanoma. Ann Surg 1975;182(5):572–5. Cross Ref link Pubmed link .
- 226 Predicting five‐year outcome for patients with cutaneous melanoma in a population‐based study. Cancer 1996;78(3):427–32. Cross Ref link Pubmed link , , , .
- 227 Time and frequency of recurrence of cutaneous stage I malignant melanoma with guidelines for follow‐up study. Surg Gynecol Obstet 1988;166(6):497–502. Pubmed link , , , .
- 228 A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 1981;193(3):377–88. Cross Ref link Pubmed link , , , et al.
- 229 The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51–3.99 mm). Cancer 1985;56(2):413–18. Cross Ref link Pubmed link , , , et al.
- 230 Prognostic index in malignant melanoma. Arch Dermatol 1978;114(6):871–3. Cross Ref link Pubmed link , .
- 231 Low‐ and high‐risk malignant melanoma – II. Multivariate analyses for a prognostic classification. Eur J Cancer Clin Oncol 1983;19(2):237–43. Cross Ref link Pubmed link , , , .
- 232 Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas. J Clin Oncol 2007;25(9):1129–34. Cross Ref link Pubmed link , , , et al.
- 233 The prognostic importance of tumor mitotic rate for patients with primary cutaneous melanoma. Ann Surg Oncol 2004;11(4):360–1. Cross Ref link Pubmed link .
- 234 Long‐term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa‐2b versus observation in resected stage III melanoma. J Clin Oncol 2012;30(31):3810–18. Cross Ref link Pubmed link , , , et al.
- 235 Lymphovascular invasion as a prognostic factor in melanoma. Am Surg 2011;77(8):992–7. Pubmed link , , , et al.
- 236 Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst 1989;Dec 20;81(24):1893–904. Cross Ref link Pubmed link , , , et al.
- 237 Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993;71:3737. Cross Ref link Pubmed link , , et al.
- 238 Experience with 998 cutaneous melanomas of the head and neck over 30 years. Am J Surg 1991;Oct;162(4):310–14. Cross Ref link Pubmed link , , , et al.
- 239 Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer 1995;May 15;75(10):2492–8. Cross Ref link Pubmed link , , , et al.
- 240 Age as a prognostic factor in the malignant melanoma population. Ann Surg Oncol 1994;1(6):487–94. Cross Ref link Pubmed link , , , et al.
- 241 Histologic features of tumors and the female superiority in survival from malignant melanoma. Cancer 1980;45(7):1604–8. Cross Ref link Pubmed link , , , et al.
- 242 An analysis of prognostic factors in 8500 patients with cutaneous melanoma. In: Balch CM, Houghton AN, Milton GW, Sober AJ, Soong SJ, eds. Cutaneous Melanoma, 2nd edn. Philadelphia: Lippincott, 1992:165–87. , , , et al.
- 243 Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med 2006;Sep 28;355(13):1307–17. Cross Ref link Pubmed link , , , et al.
- 244 Sentinel lymph node molecular ultrastaging in patients with melanoma: a systematic review and meta‐analysis of prognosis. J Clin Oncol 2007;25(12):1588–95. Cross Ref link Pubmed link , , , et al.
- 245 Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med 2014;Feb 13;370(7):599–609. Cross Ref link Pubmed link , , , et al.
- 246 Influence of fast lymphatic drainage on metastatic spread in cutaneous malignant melanoma: a prospective feasibility study. Eur J Nucl Med Mol Imaging 2003;30(4):538–44. Cross Ref link Pubmed link , , , et al.
- 247 Slow dynamics of lymphoscintigraphic mapping is associated to the negativity of the sentinel node in melanoma patients. Ann Surg Oncol 2008;15(10):2878–86. Cross Ref link Pubmed link , , , et al.
- 248 Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009;27(36):6199–206. Cross Ref link Pubmed link , , , et al.
- 249 Risk of second primary in situ and invasive melanoma in a Dutch population‐based cohort: 1989–2008. Br J Dermatol 2012;D;167(6):1321–30. Cross Ref link Pubmed link , , , et al.
- 250 Site and timing of first relapse in stage III melanoma patients: implications for follow‐up guidelines. J Clin Oncol 2010;28:3042–7. Cross Ref link Pubmed link , , , et al.
- 251 Comparison of melanoma guidelines in the U.S.A., Canada, Europe, Australia and New Zealand: a critical appraisal and comprehensive review. Br J Dermatol 2014;170:20–30. Cross Ref link Pubmed link , .
- 1 Thin primary cutaneous melanomas: associated detection patterns, lesion characteristics, and patient characteristics. Cancer 2002 Oct 1;95(7):1562–8. Cross Ref link Pubmed link , , , , , .
- 2 What features do patients notice that help to distinguish between benign pigmented lesions and melanomas? The ABCD(E) rule versus the seven‐point checklist. Melanoma Res 2005 Dec;15(6):549–54. Cross Ref link Pubmed link , , , et al.
- 3 Early detection of malignant melanoma: the role of physician examination and self‐examination of the skin. Cancer J Clin 1985 May–Jun;35(3):130–51. Cross Ref link , , .
- 4 Early diagnosis of cutaneous melanoma: revisiting the ABCD criteria. JAMA 2004 Dec 8;292(22):2771–6. Cross Ref link Pubmed link , , , et al.
- 5 First prospective study of the recognition process of melanoma in dermatological practice. Arch Dermatol 2005 Apr;141(4):434–8. Cross Ref link Pubmed link , , , et al.
- 6 Non‐radical diagnostic biopsies do not negatively influence melanoma patient survival. Ann Surg Oncol 2007 Apr;14(4):1424–30. Cross Ref link Pubmed link , , , , .
- 7 Microstaging accuracy after subtotal incisional biopsy of cutaneous melanoma. J Am Acad Dermatol 2005 May;52(5):798–802. Cross Ref link Pubmed link , , , et al.
- 8 Pathology review of cases presenting to a multidisciplinary pigmented lesion clinic. Arch Dermatol 2002 May;138(5):617–21. Pubmed link , , , et al.
- 9 Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol 1996 Jun;27(6):528–31. Cross Ref link Pubmed link , , .
- 10 Interobserver variability on the histopathologic diagnosis of cutaneous melanoma and other pigmented skin lesions. J Clin Oncol 1996 Apr;14(4):1218–23. Pubmed link , , , et al.
- 11 Melanoma. J Natl Comp Cancer Network 2012 Mar;10(3):366–400. , , , et al.
- 12 Narrow excision (1‐cm margin). A safe procedure for thin cutaneous melanoma. Arch Surg 1991 Apr;126(4):438–41. Cross Ref link Pubmed link , .
- 13 Thin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cm. New Engl J Med 1988 May 5;318(18):1159–62. Cross Ref link Pubmed link , , , et al.
- 14 Margin of resection in the management of primary melanoma. Semin Surg Oncol 1998 Jun;14(4):272–5. Cross Ref link Pubmed link .
- 15 Long term results of a randomized study by the Swedish Melanoma Study Group on 2‐cm versus 5‐cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8‐2.0 mm. Cancer 2000 Oct 1;89(7):1495–501. Cross Ref link Pubmed link , , , et al.
- 16 Long‐term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1‐4 mm melanomas. Ann Surg Oncol 2001 Mar;8(2):101–8. Pubmed link , , , et al.
- 17 Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1‐mm thick). Cancer 2003 Apr 15;97(8):1941–6. Cross Ref link Pubmed link , , , et al.
- 18 Excision margins in high‐risk malignant melanoma. New Engl J Med 2004 Feb 19;350(8):757–66. Cross Ref link Pubmed link , , , et al.
- 19 Surgical excision margins for primary cutaneous melanoma. Cochrane Syst Rev 2009 (4):CD004835. , , , et al.
- 20 Melanoma, version 2. 2013: featured updates to the NCCN guidelines. J Natl Comp Cancer Network 2013 Apr 1;11(4):395–407. , , , et al.
- 21 Guidelines of care for the management of primary cutaneous melanoma. American Academy of Dermatology. J Am Acad Dermatol 2011 Nov;65(5):1032–47. Cross Ref link Pubmed link , , , et al.
- 22 Histological characteristics of metastasizing thin melanomas: a case–control study of 43 cases. Arch Dermatol 2002 May;138(5):603–8. Pubmed link , , , et al.
- 23 Mohs micrographic excision of melanoma using immunostains. Dermatol Surg 2000 Aug;26(8):771–84. Cross Ref link Pubmed link , , , .
- 24 Management of periocular cutaneous melanoma with a staged excision technique and permanent sections the square procedure. Ophthalmology 2008 Dec;115(12):2295–300 e3. Cross Ref link Pubmed link , , , , , .
- 25 Are en face frozen sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol 2003 Aug;120(2):203–8. Cross Ref link Pubmed link , , , et al.
- 26 Sentinel lymph node biopsy for melanoma: indications and rationale. Cancer Control 2009 Jul;16(3):234–9. Pubmed link , , , .
- 27 Sentinel lymph node biopsy for melanoma: a critical update for dermatologists after two decades of experience. Clin Dermatol 2013 May–Jun;31(3):298–310. Cross Ref link Pubmed link , .
- 28 Inefficacy of immediate node dissection in stage 1 melanoma of the limbs. N Engl J Med 1977 Sep 22;297(12):627–30. Cross Ref link Pubmed link , , , et al.
- 29 Lymphadenectomy in the management of stage I malignant melanoma: a prospective randomized study. Mayo Clin Proc 1986 Sep;61(9):697–705. Cross Ref link Pubmed link , , , .
- 30 Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma Programme. Lancet 1998 Mar 14;351(9105):793–6. Cross Ref link Pubmed link , , , , .
- 31 Long‐term results of a multi‐institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 2000 Mar;7(2):87–97. Cross Ref link Pubmed link , , , et al.
- 32 Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg 1992 Apr;127(4):392–9. Cross Ref link Pubmed link , , , et al.
- 33 Sentinel lymph node status as an indicator of the presence of metastatic melanoma in regional lymph nodes. Melanoma Res 1995 Aug;5(4):255–60. Cross Ref link Pubmed link , , , et al.
- 34 Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 1993 May–Jun;9(3):219–23. Pubmed link , , .
- 35 Lymphatic mapping and sentinel lymph node biopsy in patients with melanoma: a meta‐analysis. J Clin Oncol 2011 Apr 10;29(11):1479–87. Cross Ref link Pubmed link , , , , .
- 36 Sentinel node biopsy for head and neck melanoma: a systematic review. Otolaryngol Head Neck Surg 2011 Sep;145(3):375–82. Cross Ref link Pubmed link , , , et al.
- 37 Association between sentinel lymph node excision with or without preoperative SPECT/CT and metastatic node detection and disease‐free survival in melanoma. JAMA 2012 Sep 12;308(10):1007–14. Cross Ref link Pubmed link , , , et al.
- 38 Sentinel lymph node biopsy in melanoma: controversies and current guidelines. Future Oncol 2014 Feb;10(3):429–42. Cross Ref link Pubmed link , .
- 39 Diagnosis and treatment of melanoma. European consensus‐based interdisciplinary guideline – Update 2012. Eur J Cancer 2012 Oct;48(15):2375–90. Cross Ref link Pubmed link , , , et al.
- 40 Evidence and interdisciplinary consensus‐based German guidelines: surgical treatment and radiotherapy of melanoma. Melanoma Res 2008 Feb;18(1):61–7. Cross Ref link Pubmed link , , , et al.
- 41 Australian Cancer Network Melanoma Guidelines Revision Working Party (Party ACNMGRW). Clinical Practice Guidelines for the Management of Melanoma in Australia and New Zealand. Wellington: Cancer Council Australia and Australian Cancer Network, Sydney and New Zealand Guidelines Group, 2008 http://www.cancer.org.au/content/pdf/HealthProfessionals/ClinicalGuidelines/ClinicalPracticeGuidelines‐ManagementofMelanoma.pdf (last accessed August 2015).
- 42 Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 2012 Aug 10;30(23):2912–18. Cross Ref link Pubmed link , , , et al.
- 43 Final trial report of sentinel‐node biopsy versus nodal observation in melanoma. N Engl J Med 2014 Feb 13;370(7):599–609. Cross Ref link Pubmed link , , , et al.
- 44 Sentinel‐node biopsy or nodal observation in melanoma. N Engl J Med 2006 Sep 28;355(13):1307–17. Cross Ref link Pubmed link , , , et al.
- 45 The impact on morbidity and length of stay of early versus delayed complete lymphadenectomy in melanoma: results of the Multicenter Selective Lymphadenectomy Trial (I). Ann Surg Oncol 2010 Dec;17(12):3324‐9. Cross Ref link Pubmed link , , , et al.
- 46 Inguinal node dissection for melanoma in the era of sentinel lymph node biopsy. Surgery 2007 Jun;141(6):728–35. Cross Ref link Pubmed link , , , et al.
- 47 Sentinel node biopsy for thin melanomas: which patients should be considered? Cancer Control 2005 Oct;12(4):230–5. Pubmed link , , , et al.
- 48 Role of sentinel lymph node biopsy in patients with thin melanoma. J Natl Comp Cancer Network 2009 Mar;7(3):308–17. , .
- 49 Sentinel lymph node biopsy in patients with thin primary cutaneous melanoma. Ann Surg 2012 Jan;255(1):128–33. Cross Ref link Pubmed link , , , et al.
- 50 The role of sentinel lymph node biopsy in the management of thin melanoma. Am J Surg 2005 Aug;190(2):196–9. Cross Ref link Pubmed link .
- 51 Role of sentinel lymphadenectomy in thin invasive cutaneous melanomas. J Clin Oncol 2003 Apr 1;21(7):1326–31. Cross Ref link Pubmed link , , , , .
- 52 Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009 Dec 20;27(36):6199–206. Cross Ref link Pubmed link , , , et al.
- 53 Overview and update of the phase III Multicenter Selective Lymphadenectomy Trials (MSLT‐I and MSLT‐II) in melanoma. Clin Exp Metastasis 2012 Oct;29(7):699–706. Cross Ref link Pubmed link .
- 54 Completion lymph node dissection after a positive sentinel node: no longer a must? Curr Opin Oncol 2013 Mar;25(2):152–9. Cross Ref link Pubmed link , , , .
- 1 Long‐term pegylated interferon‐alpha and its potential in the treatment of melanoma. Biologics 2009;3:169–82. Pubmed link , .
- 2 Randomised trial of interferon alpha‐2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma. Lancet 1998 Jun 27;351(9120):1905–10. Cross Ref link Pubmed link , , , et al.
- 3 Long‐term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa‐2b versus observation in resected stage III melanoma. J Clin Oncol 2012 Nov 1;30(31):3810–18. Cross Ref link Pubmed link , , , et al.
- 4 High‐ and low‐dose interferon alfa‐2b in high‐risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 2000 Jun;18(12):2444–58. Pubmed link , , , et al.
- 5 Interferon alfa‐2b adjuvant therapy of high‐risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996 Jan;14(1):7–17. Pubmed link , , , , , .
- 6 Interferon alpha adjuvant therapy in patients with high‐risk melanoma: a systematic review and meta‐analysis. J Natl Cancer Inst 2010 Apr 7;102(7):493–501. Cross Ref link Pubmed link , , , .
- 7 Adjuvant therapy with pegylated interferon alfa‐2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet 2008 Jul 12;372(9633):117–26. Cross Ref link Pubmed link , , , et al.
- 8 Final results of the EORTC 18871/DKG 80‐1 randomised phase III trial. rIFN‐alpha2b versus rIFN‐gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high‐risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer 2004 Feb;40(3):390–402. Cross Ref link Pubmed link , , , et al.
- 9 RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 2012 Jan 20;30(3):316–21. Cross Ref link Pubmed link , , , et al.
- 10 RAF265 inhibits the growth of advanced human melanoma tumors. Clin Cancer Res 2012 Apr 15;18(8):2184–98. Cross Ref link Pubmed link , , , et al.
- 11 Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol 2012 Jul 1;30(19):2375–83. Cross Ref link Pubmed link , , , et al.
- 12 Isolated limb perfusion with melphalan in the treatment of malignant melanoma of the extremities: a systematic review of randomised controlled trials. Lancet Oncol 2003 Jun;4(6):359–64. Cross Ref link Pubmed link , .
- 13 Long‐term outcome of hyperthermic isolated limb perfusion (HILP) in the treatment of locoregionally metastasised malignant melanoma of the extremities. Int J Hyperthermia 2010 Feb;26(1):16–20. Cross Ref link Pubmed link , , , et al.
- 14 Role of radiation therapy in cutaneous melanoma. Cancer J 2012 Mar–Apr;18(2):203–7. Cross Ref link Pubmed link , .
- 15 Adjuvant radiotherapy versus observation alone for patients at risk of lymph‐node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol 2012 Jun;13(6):589–97. Cross Ref link Pubmed link , , , et al.
- 16 Antitumor effectiveness of electrochemotherapy: a systematic review and meta‐analysis. Eur J Surg Oncol 2013 Jan;39(1):4–16. Cross Ref link Pubmed link , , , , .
- 17 Vaccination of melanoma patients with peptide‐ or tumor lysate‐pulsed dendritic cells. Nat Med 1998 Mar;4(3):328–32. Cross Ref link Pubmed link , , , et al.
- 18 Nano‐particle vaccination combined with TLR‐7 and ‐9 ligands triggers memory and effector CD8(+) T‐cell responses in melanoma patients. Eur J Immunol 2012 Nov;42(11):3049–61. Cross Ref link Pubmed link , , , et al.
- 19 Multicenter, randomized phase II trial of GM‐CSF (GM) plus ipilimumab (Ipi) versus Ipi alone in metastatic melanoma: E1608. J Clin Oncol 2013;31(Suppl.; abstr. CRA9007). Cross Ref link , , , et al.
- 20 Tumor‐associated B7‐H1 promotes T‐cell apoptosis: a potential mechanism of immune evasion. Nat Med 2002 Aug;8(8):793–800. Cross Ref link Pubmed link , , , et al.
- 21 The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012 Apr;12(4):252–64. Cross Ref link Pubmed link .
- 22 Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med 2012 Jun 28;366(26):2443–54. Cross Ref link Pubmed link , , , et al.
- 23 PD‐1‐targeted immunotherapy: recent clinical findings. Clin Adv Hematol Oncol 2012 Oct;10(10):674–5. Pubmed link .
- 24 Safety and tumor responses with lambrolizumab (anti‐PD‐1) in melanoma. N Engl J Med 2013 Jul 11;369(2):134–44. Cross Ref link Pubmed link , , , et al.
- 25 Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013 Jul 11;369(2):122–33. Cross Ref link Pubmed link , , , et al.
- 26 High‐dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999;17(7):2105–16. Pubmed link , , , et al.
- 27 Single‐agent interleukin‐2 in the treatment of metastatic melanoma. Curr Oncol 2007;14(1):21–6. Cross Ref link Pubmed link , , , et al.
- 28 Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011 Jun 30;364(26):2507–16. Cross Ref link Pubmed link , , , et al.
- 29 Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010 Aug 26;363(9):809–19. Cross Ref link Pubmed link , , , et al.
- 30 Dabrafenib in patients with Val600Glu or Val600Lys BRAF‐mutant melanoma metastatic to the brain (BREAK‐MB): a multicentre, open‐label, phase 2 trial. Lancet Oncol 2012 Nov;13(11):1087–95. Cross Ref link Pubmed link , , , et al.
- 31 (V600E)BRAF is associated with disabled feedback inhibition of RAF‐MEK signaling and elevated transcriptional output of the pathway. Proc Natl Acad Sci U S A 2009 Mar 17;106(11):4519–24. Cross Ref link Pubmed link , , , et al.
- 32 Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF‐mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol 2013 Feb 1;31(4):482–9. Cross Ref link Pubmed link , , , et al.
- 33 Phase II, open‐label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 2012 Jan 15;18(2):555–67. Cross Ref link Pubmed link , , , et al.
- 34 MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non‐randomised, open‐label phase 2 study. Lancet Oncol 2013 Mar;14(3):249–56. Cross Ref link Pubmed link , , , et al.
- 35 Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012 Nov;367(18):1694–703. Cross Ref link Pubmed link , , , et al.
- 36 Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015;372(1):30–9. Cross Ref link Pubmed link , , , et al.
- 37 Combined vemurafenib and cobimetinib in BRAF‐mutated melanoma. N Engl J Med 2014;371(20):1867–76. Cross Ref link Pubmed link , , , et al.
- 38 BRAF mutation predicts sensitivity to MEK inhibition. Nature 2006 Jan 19;439(7074):358–62. Cross Ref link Pubmed link , , , et al.
- 39 RASopathic skin eruptions during vemurafenib therapy. PLOS One 2013;8(3):e58721. Cross Ref link Pubmed link , , , et al.
- 40 Cutaneous manifestations of dabrafenib (GSK2118436): a selective inhibitor of mutant BRAF in patients with metastatic melanoma. Br J Dermatol 2012 Nov;167(5):1153–60. Cross Ref link Pubmed link , , , et al.
- 41 Ultraviolet A and photosensitivity during vemurafenib therapy. N Engl J Med 2012 Feb 2;366(5):480–1. Cross Ref link Pubmed link , , .
- 42 Dabrafenib in BRAF‐mutated metastatic melanoma: a multicentre, open‐label, phase 3 randomised controlled trial. Lancet 2012 Jul 28;380(9839):358–65. Cross Ref link Pubmed link , , , et al.
- 43 Phase I pharmacokinetic and pharmacodynamic study of the oral, small‐molecule mitogen‐activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY‐142886) in patients with advanced cancers. J Clin Oncol 2008 May 1;26(13):2139–46. Cross Ref link Pubmed link , , , et al.
- 44 , , , et al. Self limiting serous retinopathy‐like toxicity during MEK Kinase inhibition. Poster 32, EADO Meeting Barcelona, November, 2012.
- 45 Cutaneous drug eruptions associated with the use of new oncological drugs. Chem Immunol Allergy 2012;97:191–202. Cross Ref link Pubmed link , , , , .
- 46 Mitogen‐activated protein/extracellular signal‐regulated kinase kinase inhibition results in biphasic alteration of epidermal homeostasis with keratinocytic apoptosis and pigmentation disorders. Clin Cancer Res 2010 Feb 1;16(3):1058–64. Cross Ref link Pubmed link , , , et al.
- 47 Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 2012;367(18):1694–703. Cross Ref link Pubmed link , , , et al.
- 48 Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991. Eur J Cancer 2012;48(2):218–25. Cross Ref link Pubmed link , , , et al.
- 49 Modelling vemurafenib resistance in melanoma reveals a strategy to forestall drug resistance. Nature 2013 Feb 14;494(7436):251–5. Cross Ref link Pubmed link , , , et al.
- 50 Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 2006 Sep 10;24(26):4340–6. Cross Ref link Pubmed link , , , .
- 51 KIT as a therapeutic target in metastatic melanoma. JAMA 2011 Jun 8;305(22):2327–34. Cross Ref link Pubmed link , , , et al.
- 52 Phase II, open‐label, single‐arm trial of imatinib mesylate in patients with metastatic melanoma harboring c‐Kit mutation or amplification. J Clin Oncol 2011 Jul 20;29(21):2904–9. Cross Ref link Pubmed link , , , et al.
- 53 Phase II study of selumetinib (sel) versus temozolomide (TMZ) in gnaq/Gna11 (Gq/11) mutant (mut) uveal melanoma (UM). J Clin Oncol 2013;31(Suppl.): Abstr. CRA9003. Cross Ref link , , , et al.
- 54 Ipilimumab in patients with melanoma and brain metastases: an open‐label, phase 2 trial. Lancet Oncol 2012 May;13(5):459–65. Cross Ref link Pubmed link , , , et al.
- 55 Open‐label pilot study of vemurafenib in previously treated metastatic melanoma (mm) patients (pts) with symptomatic brain metastases (bm). Ann Oncol 2012; ESMO, Vienna, Abstr. 2720. Pubmed link , , , et al.
- 56 Temozolomide for the treatment of metastatic melanoma. Curr Oncol 2007;14(1):27–33. Cross Ref link Pubmed link , , , , .
- 57 Temozolomide in combination with celecoxib in patients with advanced melanoma. A phase II study of the Hellenic Cooperative Oncology Group. Ann Oncol 2006 Dec;17(12):1835–41. Cross Ref link Pubmed link , , , et al.
- 58 Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev 2007(1):CD005413. Pubmed link , , , , .
- 59 Phase 3, randomized, open‐label, multicenter trial of nab‐paclitaxel (nab‐P) vs dacarbazine (DTIC) in previously untreated patients with metastatic malignant melanoma (MMM). Pigment Cell Melanoma Res 2012;25(6):863. , , , et al.
- 60 First‐line temozolomide combined with bevacizumab in metastatic melanoma: a multicentre phase II trial (SAKK 50/07). Ann Oncol 2012 Feb;23(2):531–6. Cross Ref link Pubmed link , , , et al.
- 61 BEAM: a randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012 Jan 1;30(1):34–41. Cross Ref link Pubmed link , , , et al.
- 62 Targeting the RAS pathway in melanoma. Trends Mol Med 2012 Jan;18(1):27–35. Cross Ref link Pubmed link , , .